We discuss the problem of Poincaré recurrences in area-preserving maps and the universality of their decay at long times. The work is related to to the results presented in Refs. [1,2] The first one states that the asymptotic decay P (τ ) ∝ 1/τ 3 , which is expected from the scaling theory of universal phase-space structure in the vicinity of critical golden curve (see Refs. 1-2, 12-18 in [2]), is not valid. Such a conclusion is based on where N tot = 10 12 . New data for 8 < log τ ≤ 9 indeed demonstrate noticeable deviations from the theoretical estimates for P (τ ) obtained from the exit times τ n from golden resonance scales r n (Fig. 1 in [2]). These deviations are rather intriguing. Indeed, the local properties of critical golden curve are known to be self-similar and universal (e.g. phase-space structure, size of resonances and local diffusion rate, see e.g. Refs. 2, 15 in [2]). Moreover, the exit times τ n , found in [2] for a first time, give an example of a non-local characteristic which follows the universal scaling law. The arguments based on this scaling lead to the asymptotic decay P (τ ) ∝ 1/τ 3 which however can start after extremely long times τ > τ a . In [2] we have shown that at least τ a > τ g ≈ 2×10 5 and it is not excluded that this time scale is still much longer [3], and is not yet reached even in the simulations presented in [1].If to assume this then there is an interesting possibility to see if P (τ ) would have some universal properties on the presently available (intermediate) time scales (τ ≤ 10 9 ). This is the second aspect of the quarry on which the authors of the Comment tend to give a negative answer. To this end we show in Fig.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.